The APPROVe trial, in 2005, documented relatively few stroke events and demonstrated a trend toward increased stroke risk with rofecoxib, but this did not reach statistical significance. 4 The APC (Adenoma Prevention with Celecoxib) trial assessed the use of either 400 mg or 800 mg of celecoxib for the prevention of colorectal adenomas. 27 A composite cardiovascular endpoint was used, thus a specific analysis for stroke was not performed.
1
—
—